Peregrine Pharmaceuticals has presented a range of clinical, translational, and pre-clinical study results of bavituximab, an investigational phosphatidylserine (PS)-signalling pathway inhibitor.
According to the firm, the study results demonstrated that bavituximab has promoted anti-tumour T cell activity in several tumour types.
Go deeper with GlobalData
Preclinical data showed that combining the enhanced T cell anti-tumour activity of bavituximab-like antibodies with checkpoint inhibitors, such as anti-PD-1 antibodies results in better tumour control in multiple models of cancer.
Peregrine Pharmaceuticals preclinical research vice-president Jeff Hutchins said: "We continue to generate a broad collection of pre-clinical, translational and clinical data highlighting bavituximab’s novel mechanism of action and synergistic activity for a range of combination treatments."
The study also showed that bavituximab-like antibodies significantly increase the prevalence of tumour infiltrating CD8+ T-cells and immune-activating cytokines, while decreasing macrophages and myeloid cells that allow the tumour to evade immune detection.
The data of translational study across multiple cancers suggested that tumours with low PD-L1 or PD-1 expression on tumour infiltrating T cells showed promising signs of immune activation after treatment with bavituximab.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe elucidation and confirmation of bavituximab’s mechanism of action represents the potential of bavituximab to enhance the anti-tumour effects of both chemotherapy and immune checkpoint inhibitors.
In addition, the combination of bavituximab-like antibodies and anti-PD-1 antibodies resulted in enhanced and synergistic anti-tumour activity in animal models of multiple tumour types compared to either agent alone.
Results from several clinical and preclinical studies in a range of tumour types demonstrated that bavituximab and bavituximab-like antibodies, in combination with conventional therapy, have consistently showed estimated survival curves that plateau.
